Please provide your email address to receive an email when new articles are posted on . Percent predicted FEV 1 did not improve after systemic corticosteroid treatment. This treatment was also not ...
Cost-effectiveness of NALIRIFOX compared to other first-line treatments for metastatic pancreatic cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results